ABSTRACT: Sativex is an emergent treatment option for spasticity in patients affected by multiple sclerosis (MS). This oromucosal spray, acting as a partial agonist at cannabinoid receptors, may modulate the balance between excitatory and inhibitory neurotransmitters, leading to muscle relaxation that is in turn responsible for spasticity improvement. Nevertheless, since the ... Continue Reading
Sativex®
Cannabinoids Play a Role in Treating an Aggressive Adult Cancer
In one of the most aggressive adult cancers, cannabinoids have been found to disrupt tumour growth or start to kill it, depending on the cell type. In this post from Humanity+ Media, Dr. Wai Liu discusses how the study showed that combining radiotherapy with cannabinoid treatment had a big effect: Widely prescribed around the world for its recreational uses, cannabis is ... Continue Reading
STUDY: Multiple Sclerosis – Sativex-induced neurobehavioral effects: causal or concausal? A practical advice!
ABSTRACT: Nabiximols (Sativex) is an oromucosal spray, containing delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD), used as treatment for unresponsive spasticity in multiple sclerosis (MS) patients. Sativex is thought to not affect cognition or induce any psychiatric problem at the doses generally used. Nonetheless, it is known that the concomitant use of more than one ... Continue Reading
STUDY: Anxiety – Subjective and Physiological Effects After Controlled Sativex and Oral THC Administration
ABSTRACT: Sativex is a cannabis-plant extract delivering nearly 1:1 Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) by oromucosal spray. It has been suggested that CBD attenuates THC-induced tachycardia, anxiety, and euphoria. In this study, pharmacodynamic effects were compared over 10.5 h in nine cannabis smokers randomly assigned to receive placebo, 5 and 15 mg ... Continue Reading
STUDY: Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?
ABSTRACT: OBJECTIVES We characterize cannabinoid disposition in oral fluid (OF) after Dronabinol, synthetic oral Δ9-tetrahydrocannabinol (THC), and Sativex, a cannabis-extract oromucosal spray, and evaluate whether smoked cannabis relapse or Sativex compliance can be identified with OF cannabinoid monitoring. METHODS 5 and 15 mg synthetic oral THC, low (5.4 mg THC, ... Continue Reading